• Price (USD)307.99
  • Today's Change8.40 / 2.80%
  • Shares traded413.20k
  • 1 Year change+1.28%
  • Beta1.4559
Data delayed at least 15 minutes, as of Aug 12 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Gartner, Inc. is a research and advisory company. It is an advisor and objective resource for more than 15,000 enterprises in approximately 100 countries. The Company’s segments include Research, which delivers independent and objective advice to leaders across an enterprise through subscription services that include on-demand access to published research content, data, and benchmarks; Conferences, which are designed for information technology (IT) and business executives as well as decision makers looking to adapt and evolve their organizations through disruption and uncertainty, navigate risks and prioritize investments, and Consulting, which serves chief information officers and other senior executives who are driving technology-related strategic initiatives to optimize technology investments and drive business impact. Additionally, it provides solutions for a range of IT-related priorities, including IT cost optimization, digital transformation, and IT sourcing optimization.

  • Revenue in USD (TTM)5.10bn
  • Net income in USD735.66m
  • Incorporated1990
  • Employees16.60k
  • Location
    Gartner Inc56 Top Gallant RdPO Box 10212STAMFORD 06904-2212United StatesUSA
  • Phone+1 (203) 964-0096
  • Fax+1 (302) 636-5454
  • Websitehttps://www.gartner.com/en
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
BIO-TECHNE Corp-100.00bn-100.00bn14.17bn2.60k--8.76----------43.36------------------------2.64--0.1308----------24.23--
Horizon Therapeutics PLC3.81bn764.96m15.46bn2.02k21.133.1913.724.133.243.2416.1421.470.4474.065.412,017,520.008.973.939.924.6475.3971.3720.0610.983.7911.270.34170.0046.6326.8837.12--37.25--
Incyte Corporation3.32bn945.01m16.40bn2.09k17.444.0316.374.974.254.2514.9118.410.724.375.921,585,708.0020.495.8924.757.0595.3295.8828.467.983.857.770.00830.0011.9821.98420.8055.538.52--
Cardinal Health Inc176.85bn-955.00m16.83bn47.30k------0.0967-3.55-3.55621.06-2.554.1111.4318.643,738,837.00-2.22-0.5466-5.97-1.293.634.70-0.5395-0.1510.5369.651.14--6.245.98116.53-15.60-2.974.66
Biomarin Pharmaceutical Inc1.91bn50.15m17.75bn3.05k414.763.95114.449.310.23150.252810.2124.290.31750.61244.29627,819.100.8328-0.9720.9007-1.1275.7676.742.62-2.913.69-8.500.1935---0.762210.58-1,590.90---4.28--
ICON PLC7.59bn209.90m18.79bn39.30k96.622.4325.452.612.522.5292.3599.920.736--4.80197,976.302.077.222.509.5327.7330.262.819.57--3.010.3825--95.9326.88-53.91-10.1917.09--
Catalent Inc4.70bn486.90m19.38bn17.30k40.624.3624.134.302.782.7826.8225.880.49274.974.14271,861.305.384.206.074.7833.8332.1410.928.332.235.280.47470.0029.2116.69205.7836.5337.50--
Gartner Inc5.10bn735.66m23.23bn16.60k33.90--25.394.668.868.8661.35-1.800.7405--4.39307,341.3010.684.1219.137.0669.4265.0014.426.65--12.971.06--15.4814.13197.5032.603.71--
Alnylam Pharmaceuticals, Inc.884.25m-980.72m26.81bn1.67k--159.45--31.49-8.17-8.177.371.450.25861.697.19531,078.10-28.68-32.56-34.85-37.9483.40---110.91-223.643.62-2.990.7938--71.3178.070.6358--3.42--
DuPont de Nemours Inc15.14bn1.23bn29.37bn28.00k25.391.1911.472.012.393.6529.3850.960.33543.965.94540,642.902.87-0.22273.25-0.28934.6331.608.56-1.612.125.060.3016--16.15-19.13172.14-15.09-25.20-26.30
AmerisourceBergen Corp.236.33bn1.84bn29.99bn38.00k16.71134.9111.970.12778.718.711,117.751.084.1814.8012.096,219,
Seagen Inc1.78bn-739.80m32.39bn2.68k--11.04--18.22-4.04-4.049.7015.910.46891.504.35664,625.40-19.51-5.22-22.62-6.0079.5887.67-41.61-9.784.04-211.850.00---27.6330.36-209.91--13.46--
Data as of Aug 12 2022. Currency figures normalised to Gartner Inc's reporting currency: US Dollar USD

Institutional shareholders

42.38%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20228.78m10.90%
BAMCO, Inc.as of 31 Mar 20225.27m6.55%
BlackRock Fund Advisorsas of 30 Jun 20224.03m5.01%
SSgA Funds Management, Inc.as of 31 Mar 20223.22m4.00%
Polen Capital Management LLCas of 30 Jun 20223.00m3.72%
Fidelity Management & Research Co. LLCas of 30 Jun 20222.26m2.81%
Generation Investment Management LLPas of 30 Jun 20222.25m2.79%
Wellington Management Co. LLPas of 31 Mar 20222.03m2.52%
Atlanta Capital Management Co. LLCas of 30 Jun 20221.73m2.15%
Geode Capital Management LLCas of 30 Jun 20221.56m1.93%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.